Peply
← All Compounds

Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

BPC-157

Removed from Cat 2

Growth & Recovery · Research peptide (multiple suppliers)

Gastric pentadecapeptide researched for tissue repair, angiogenesis, and anti-inflammatory effects. Not FDA-approved for any indication.

About

Mechanism
Gastric pentadecapeptide. Promotes angiogenesis, supports tendon and ligament healing, and modulates nitric oxide signaling and growth factor expression.
Half-Life
Estimated 15-30 minutes (rapid plasma clearance)
Route
subcutaneous
Frequency
1-2x daily

Clinical Dosing

200-800 mcg1-2x daily

Removed from Category 2 following the April 2026 FDA announcement. Will undergo PCAC review starting July 2026. Remains for research use only until final decision.

Dosing extrapolated from animal studies and community protocols. No large-scale human clinical trials.

Regulatory Status

FDA Category
Research peptide (removed from FDA Category 2)
Reclassification
removed-from-cat2
Date Restricted
2023-09-29
Announced Return
2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Dosing Protocol

Source: Sikiric et al., Current Pharmaceutical Design, 2018

DoseDurationDraw (5 mg vial in 2mL)Notes
250 mcgMaintenance0.10 mL (10 units)Typical research dose, no titration

Available Vial Sizes

5 mg

5 mg vial

10 mg

10 mg vial

Citations

  1. [1]Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157: Vascular Recruitment and Gastrointestinal Tract Healing. Current Pharmaceutical Design, 24(18), 1990-2001. Link(Reviewed: 2026-04-16)